Why the study?
Does intra-arterial adriamycin induce tumor response in patients with regionally advanced neoplasms?
Does intra-arterial adriamycin induce tumor response in patients with regionally advanced neoplasms?
Answers are grounded in this paper and cite their sources.
Intra-arterial adriamycin can be administered and may induce prompt partial responses in selected patients with regionally advanced neoplasms.
Adriamycin was given by an infra-arterial route as part of a planned program of combined modality therapy in 10 patients with regionally advanced neoplasms. Doses ranged from 45–107 mg/m2 given as a continuous infusion over 1.5–3.0 days. Adriamycin was followed by radiation therapy and/or radical surgical excision of the tumor in most cases, making long-term evaluation of response difficult. However, 4 of 7 evaluable patients had prompt partial responses prior to subsequent treatment. We conclude that adriamycin can be administered by the intra-arterial route and that it may be useful as part of a program of combined modality therapy in selected patients. Cancer 33:1485–1490, 1974.
No takes yet. Share an insight, caveat, or question.
Haskell et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: